Neglected Tropical Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease (Dengue, Rabies, Trachoma, Buruli Ulcer, Yaws, Leprosy, Chagas Disease, Leishmaniasis, Soil-transmitted Helminthiases, and Others), By Product (Drugs and Vaccines), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 7.99 Billion
CAGR (2026-2031)	5.77%
Fastest Growing Segment	Dengue
Largest Market	North America
Market Size (2031)	USD 11.19 Billion

Market Overview

The Global Neglected Tropical Disease (NTD) Treatment Market will grow from USD 7.99 Billion in 2025 to USD 11.19 Billion by 2031 at a 5.77% CAGR. The Global Neglected Tropical Disease (NTD) Treatment Market encompasses the development and distribution of pharmaceuticals and medical interventions designed to combat communicable conditions prevalent in tropical climates, such as lymphatic filariasis and soil-transmitted helminthiases. The market is primarily driven by large-scale medication donation programs coordinated by multinational pharmaceutical corporations and substantial funding from philanthropic organizations which subsidize research and access costs. Furthermore, government-led initiatives for mass drug administration act as a critical support mechanism, creating sustained demand for therapeutics and ensuring systematic deployment to at-risk populations.

However, a significant challenge impeding market expansion is the inadequate healthcare infrastructure in many endemic regions, which creates severe logistical bottlenecks for last-mile delivery to remote communities. This lack of reliable supply chains often disrupts treatment continuity and limits the effective reach of global health programs. According to the International Federation of Pharmaceutical Manufacturers & Associations, in 2023, approximately 900 million people worldwide received treatment for a neglected tropical disease, highlighting the massive operational scale required to address these conditions despite logistical hurdles.

Key Market Drivers

Strategic Implementation of the WHO 2030 Roadmap and Eradication Targets acts as a primary catalyst for the market, shifting the operational focus from disease control to total interruption of transmission. This global policy framework incentivizes national governments to integrate NTD programs into their central health systems, thereby increasing the procurement of diagnostic tools and therapeutic regimens necessary for certification. The roadmap's emphasis on measurable milestones compels sustained demand for post-treatment surveillance technologies and ensures that medication stockpiles are maintained until elimination is verified. According to Uniting to Combat NTDs, December 2024, in the '2024: A year in review', the global effort reached a critical milestone with a total of 54 countries having eliminated at least one neglected tropical disease, validating the market's trajectory toward eradication-based demand.

Escalating funding and grants from global health organizations, alongside strengthened public-private partnerships, provide the essential financial liquidity required for drug production and distribution in low-resource settings. Since commercial returns in this sector are limited, philanthropic capital and corporate donations sustain the supply chain for critical medications like praziquantel and albendazole. These collaborative ventures not only fund research for novel therapeutics but also subsidize the logistical costs of mass drug administration campaigns, bridging the gap between manufacturing and patient access. According to Uniting to Combat NTDs, October 2024, in the 'Kigali Declaration on Neglected Tropical Diseases: 2022-2024 Progress Report', international partners have mobilized US$1.7 billion in financial commitments to support these disease elimination goals. Furthermore, according to Eisai Co., Ltd., in 2025, the pharmaceutical manufacturer reported providing a cumulative total of 2.51 billion diethylcarbamazine tablets to endemic regions, illustrating the massive scale of corporate contribution underpinning market stability.

Download Free Sample Report

Key Market Challenges

The inadequacy of healthcare infrastructure in endemic regions creates a substantial barrier to the growth of the Global Neglected Tropical Disease (NTD) Treatment Market. This challenge manifests as a severe logistical bottleneck where the supply chain for essential pharmaceuticals fractures before reaching the last mile. In many target areas, the absence of reliable transportation networks, climate-controlled storage facilities, and properly equipped local clinics prevents the consistent distribution of therapeutics. Even when international donation programs successfully mobilize vast quantities of medication, these infrastructure deficits frequently result in stockouts or product expiration at regional depots. Consequently, the market struggles to convert available inventory into administered treatments, stalling the operational momentum required to sustain global health initiatives.

The direct impact of these logistical failures is a persistent disconnect between the volume of medical interventions required and the actual number of patients served. This gap limits the addressable market size by rendering a significant portion of the population inaccessible. According to the World Health Organization, in 2024, it was reported that approximately 1.62 billion people globally required interventions for neglected tropical diseases. This statistic underscores that despite the availability of treatments, a massive segment of the demand remains unmet primarily due to the inability to physically deliver care. This delivery shortfall impedes market expansion by reducing the efficacy of mass drug administration campaigns and discouraging the scaling of future investment.

Key Market Trends

The Development of Pediatric-Specific Formulations and Child-Friendly Dosage Forms is emerging as a critical trend, addressing a historical treatment gap for younger demographics in endemic regions. Previously, mass drug administration campaigns were hampered by the lack of suitable options for preschool-aged children, often necessitating the inaccurate crushing of adult tablets which compromised adherence and safety. Pharmaceutical manufacturers are now prioritizing the engineering of dispersible, palatable tablets that ensure precise dosing and ease of administration for this vulnerable group. According to Merck, March 2025, in the press release 'First Preschool-Aged Child Receives Arpraziquantel for the Treatment of Schistosomiasis', the company announced the landmark administration of its newly developed dispersible tablet in an implementation study in Uganda, validating the market's progression toward inclusive therapeutic coverage for pediatric populations.

Simultaneously, the Proliferation of Product Development Partnerships (PDPs) as the Primary R&D Model is structurally reshaping the innovation landscape, effectively circumventing the limited commercial incentives that restrict private sector investment. By consolidating resources from pharmaceutical companies, academic institutions, and philanthropic entities into a virtual research engine, these consortia are successfully driving the discovery of novel compounds and repurposing strategies. This collaborative framework is essential for maintaining a viable pipeline of therapeutics that individual corporations cannot sustain in isolation. According to the Drugs for Neglected Diseases initiative (DNDi), July 2025, in the '2024 Annual Report', the organization managed a diverse portfolio of 46 R&D projects, with 21 projects specifically focused on identifying or developing new chemical entities, underscoring the dominance of the PDP model in securing future treatments.

Segmental Insights

The Dengue segment is currently the fastest-growing category in the Global Neglected Tropical Disease (NTD) Treatment Market, driven by an alarming rise in infection rates globally. Climate change and rapid urbanization have expanded mosquito habitats, necessitating urgent medical intervention in expanding geographic zones. This growth is further catalyzed by recent breakthroughs in preventative care, specifically the regulatory approval of second-generation vaccines like Takeda’s Qdenga. These advancements enable more comprehensive immunization strategies, encouraging robust procurement efforts by government health agencies and alignment with disease management frameworks established by the World Health Organization.

Regional Insights

North America holds the leading position in the Global Neglected Tropical Disease (NTD) Treatment Market, primarily due to its established pharmaceutical industry and extensive research capabilities. The region benefits from significant investments in drug development and a strong network of biotechnology firms focused on infectious diseases. Additionally, regulatory frameworks provided by the United States Food and Drug Administration (FDA), including the Tropical Disease Priority Review Voucher program, actively encourage the creation of novel therapies. These strategic incentives, alongside consistent funding from government and private health organizations, ensure North America remains the central hub for NTD treatment innovation.

Recent Developments

• In July 2024, Valneva SE received marketing authorization from the European Commission for Ixchiq, its single-dose vaccine for the prevention of chikungunya in adults. This approval followed a unanimous endorsement by member states and a positive assessment from the European Medicines Agency. As the first licensed chikungunya vaccine in Europe, this product launch addressed a critical unmet medical need for a disease that has been spreading to new geographical regions due to climate change. The authorization allowed the company to begin delivering doses to European travelers and local populations at risk of invasive mosquito attacks, strengthening preventative options in the market.
• In June 2024, the regulatory authorities of the Democratic Republic of the Congo approved the use of Fexinidazole Winthrop for the treatment of the Trypanosoma brucei rhodesiense form of sleeping sickness. This approval coincided with updated guidelines from the World Health Organization, which recommended the oral treatment as the first choice for this acute and lethal form of the disease. Developed through a collaboration between Sanofi and the Drugs for Neglected Diseases initiative, this all-oral therapy replaced older, toxic injectable treatments, significantly simplifying administration and improving patient outcomes in the Global Neglected Tropical Disease Treatment Market.
• In May 2024, Takeda announced that its dengue vaccine, Qdenga, had received prequalification from the World Health Organization. This regulatory milestone made the vaccine eligible for procurement by United Nations agencies, such as UNICEF and the Pan American Health Organization, thereby facilitating broader global access in endemic regions. The live-attenuated tetravalent vaccine was recommended for use in children aged 6 to 16 years in settings with a high dengue burden. This development represented a significant advancement in the Global Neglected Tropical Disease Treatment Market, expanding the available prophylactic tools to combat the mosquito-borne viral disease that threatens a large portion of the world's population.
• In May 2024, the World Health Organization added Arpraziquantel to its list of prequalified medicines, marking a critical development for the treatment of schistosomiasis in preschool-aged children. Developed by a consortium led by Merck, this new pediatric formulation addressed a significant gap in the Global Neglected Tropical Disease Treatment Market, as previous standard treatments were not suitable for young children due to the bitter taste and pill size. The prequalification assured that the medicine met international standards for safety and efficacy, paving the way for its procurement and distribution in endemic African countries to combat this debilitating parasitic disease.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Bayer AG
• GlaxoSmithKline plc
• Novartis AG
• Pfizer, Inc.
• Eisai Co., Ltd.
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Gilead Sciences, Inc.

By Disease	By Product	By Region
Dengue Rabies Trachoma Buruli Ulcer Yaws Leprosy Chagas Disease Leishmaniasis Soil-transmitted Helminthiases Others	Drugs and Vaccines	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Neglected Tropical Disease (NTD) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Neglected Tropical Disease (NTD) Treatment Market, By Disease:

• Dengue
• Rabies
• Trachoma
• Buruli Ulcer
• Yaws
• Leprosy
• Chagas Disease
• Leishmaniasis
• Soil-transmitted Helminthiases
• Others

• Neglected Tropical Disease (NTD) Treatment Market, By Product:

• Drugs and Vaccines

• Neglected Tropical Disease (NTD) Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE